

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

## PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 66006

Title: Encouraging Specific Biomarkers-based Therapeutic Strategies for Hepatocellular

Carcinoma

Reviewer's code: 05947170 Position: Peer Reviewer Academic degree: MD

**Professional title:** Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: China

Manuscript submission date: 2021-03-19

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-03-29 11:53

Reviewer performed review: 2021-04-06 04:35

**Review time:** 7 Days and 16 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [ Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[ ] Yes [ Y] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous  Conflicts-of-Interest: [ ] Yes [Y] No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

## SPECIFIC COMMENTS TO AUTHORS

This article reviews the biomarkers related to immunotherapy of hepatocellular carcinoma, which has very important practical significance for the combination therapy strategy of hepatocellular carcinoma. However, there were several limitations in the manuscript:1) The biomarkers listed in the manuscript are not complete, have the corresponding therapeutic drugs for the relevant biomarkers been developed, and what is the effect? 2) Whether there are any correlations between the biomarkers, what is the correlation between them and immunotherapy, respectively. Lack of some experimental data support in vitro and in vivo. It is recommended that each biomarker and pathway be listed separately.